In a recent study published in Nature, a research team from ... team analyzed tumor samples from patients with IDH-mutant and IDH-wild-type gliomas. They utilized RNA sequencing and computational ...

Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A Multilingual Overview of the INDIGO Study Data (Presented by Clinical Experts in French ...

A recent study published in MedComm – Future Medicine by a research team from Fudan University provides an in-depth ...

The Nature Medicine article looked at the case of one patient with IDH-wild-type, MGMT promoter unmethylated glioblastoma who received treatment with a single dose of triplet immunotherapy followed by ...

UCLA co-led study is first trial analyzing a targeted therapy drug specifically made for brain tumors. In an international study co-led by UCLA Health Jonsson Comprehensive Cancer Center ...

The US FDA and EMA in the EU have started accelerated reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, which is vying to become the first targeted therapy for this aggressive ...

The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer. The IDH1/2 inhibitor, which can be ...